Long‐term efficacy of 10 <scp>kHz</scp> spinal cord stimulation in managing painful diabetic neuropathy: A post‐study survey

High-frequency SCS at 10 kHz provided sustained and clinically meaningful improvements in pain and HRQoL for PDN patients at 4.1 years postimplantation, with no explants in the cohort due to inefficacy. Alongside these benefits, participants experienced metabolic changes that included reductions in body weight and HbA1c beyond that achieved at 24 months, although changes in lifestyle and medication were not accounted for in this analysis. Notably, the cohort's final mean EQ-5D-5L index score was comparable to the US norm. These findings support 10 kHz SCS as a durable and effective treatment option for PDN in routine clinical practice.

Authors

Institutions

Publication Details

Journal
Pain Practice
Published
2025-04-17
DOI
https://doi.org/10.1111/papr.70023
Citations
5
Primary Topic
Pain Management and Treatment
Type
article
Field-Weighted Citation Impact
10.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long‐term efficacy of 10 kHz spinal cord stimulation in managing painful diabetic neuropathy: A post‐study survey

Maged Guirguis, Rose Province‐Azalde, Dawood Sayed, David DiBenedetto et al.
5 citations
Pain Practice
Pain Management and Treatment
10.95
article

Long‐term efficacy of 10 kHz spinal cord stimulation in managing painful diabetic neuropathy: A post‐study survey

Maged Guirguis, Rose Province‐Azalde, Dawood Sayed, David DiBenedetto, James Scowcroft, Neel Mehta, Shawn Sills, Michael J. Jaasma, Kasra Amirdelfan, Deborah Edgar, Khalid A. Sethi, Thomas Stauss, Manish Bharara, Erika Petersen, Jijun Xu, Ali Nairizi, Shivanand P. Lad, Judith L. White, Cong Yu, Sarah Benducci
article en
5 citations

Abstract

High-frequency SCS at 10 kHz provided sustained and clinically meaningful improvements in pain and HRQoL for PDN patients at 4.1 years postimplantation, with no explants in the cohort due to inefficacy. Alongside these benefits, participants experienced metabolic changes that included reductions in body weight and HbA1c beyond that achieved at 24 months, although changes in lifestyle and medication were not accounted for in this analysis. Notably, the cohort's final mean EQ-5D-5L index score was comparable to the US norm. These findings support 10 kHz SCS as a durable and effective treatment option for PDN in routine clinical practice.

Pain PracticeVol. 25(5)
Cleveland Clinic (US), Ochsner Health System (US), University of Kansas (US), Duke University (US), Cornell University (US), Pain Management Institute (US), Swedish Medical Center (US), Kaiser Permanente Walnut Creek Medical Center (US), United Health Services (US), Nevro (United States) (US), Touchstone Research Laboratory (United States) (US), Weill Cornell Medicine (US), University of Arkansas for Medical Sciences (US)
Eli Lilly and Company, Cleveland Clinic, Boston Scientific Corporation, Saluda Medical, SPR Therapeutics, Nevro, National Institutes of Health
Openalex Percentile: Top 2%
Pain Management and Treatment
10.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.